Zynerba Pharma (ZYNE) Reports Q1 Loss of $0.60/Share

Zynerba Pharma (NASDAQ: ZYNE) reported Q1 EPS of ($0.60), versus ($0.49) reported last year.

Financial Outlook

The company believes that the current cash position of $77.5 million is sufficient to develop five Phase 3-ready programs and, assuming support from the FDA to move forward, initiate at least one Phase 3 program and fund operations and capital requirements into 2019.

For earnings history and earnings-related data on Zynerba Pharma (ZYNE) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c